Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOLERANT study of low-dose tamoxifen and lifestyle changes for breast cancer prevention
2023-503994-39-00Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tamoxifen in breast cancer (4 arms), sponsored by European Institute of Oncology. Primary endpoint: Post-intervention circulating SHBG level. Started Jun 2024; status: completed.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-503994-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503994-39-00.